Clinical Trials on Paroxysmal Hemoglobinuria, Nocturnal in Finland

Total 13 results

Ra Pharmaceuticals

Completed

Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United Kingdom, Australia, Canada, Denmark, Finland, Germany, Hungary, New Zealand
Ra Pharmaceuticals, Inc.

Terminated

Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United States, Australia, Canada, Finland, Germany, Hungary, New Zealand, United Kingdom
Alexion Pharmaceuticals, Inc.

Completed

Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab

Paroxysmal Nocturnal Hemoglobinuria

Italy, Spain, Belgium, France, Turkey, Austria, Brazil, Netherlands, Australia, Finland, Russian Federation, Sweden, Canada, United States
Alexion Pharmaceuticals, Inc.

Active, not recruiting

A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH

Paroxysmal Nocturnal Hemoglobinuria

France, Italy, Spain, United States, Thailand, Korea, Republic of, United Kingdom, Israel, Czechia, Greece, Poland, Brazil, Japan, Canada, Malaysia
Amgen

Completed

A Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Participants With PNH (DAHLIA)

Paroxysmal Nocturnal Hemoglobinuria

Spain, Italy, United States, Norway, Czechia, United Kingdom, Slovenia, Netherlands, Turkey, Portugal, Finland, France, Ireland, Sweden
Kuopio University Hospital

Terminated

Surgical Pulmonary Vein Isolation Efficiency Study (FIN-PVI)

Coronary Artery Disease | Paroxysmal Atrial Fibrillation

Finland
Helsinki University Central Hospital
University of Turku; Southern Health and Social Care Trust

Withdrawn

Voiding School as a Treatment of Children's Day-time Incontinence or Enuresis

Enuresis | Daytime Wetting | Functional Incontinence

Finland
C. R. Bard

Terminated

Study of HD Mesh Ablation System for Treatment of Paroxysmal Atrial Fibrillation (MAGELLAN)

Paroxysmal Atrial Fibrillation

United States
Boston Scientific Corporation

Completed

Boston Scientific's Cryoballoon in the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation (FROZEN-AF)

Paroxysmal Atrial Fibrillation

United States, Hong Kong, Canada, Taiwan, Belgium, France, Germany, Italy, Netherlands
Vantia Ltd

Completed

Dose Range Finding Study of Fedovapagon in Men With Nocturia

Nocturia

United States
Ferring Pharmaceuticals

Completed

A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults

Nocturia

United States, Belgium, Czechia, Hungary, Poland, Canada, Germany
Vantia Ltd

Completed

Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH) (EQUINOC)

Nocturia

United States
Edgar Jaeggi
Labatt Family Heart Centre

Recruiting

Prospective Observational Cohort Study of Fetal Atrial Flutter & Supraventricular Tachycardia (FAST Registry)

Atrial Flutter | Tachycardia, Supraventricular | Tachycardia, Atrioventricular Nodal Reentry | Tachycardia Atrial | Tachycardia, Reciprocating | Tachycardia, Paroxysmal | Fetal Hydrops | Tachycardia, Atrial Ectopic

United States, Hong Kong, Canada, Netherlands, Sweden, Australia, Brazil, Finland, France, Russian Federation, Spain, Czechia, Switzerland, United Kingdom

Clinical Trials on Paroxysmal Hemoglobinuria, Nocturnal in Finland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations